EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Results of the feasibility stage of STAMPEDE: a Multi-Arm, Multi-Stage phase II/III trial in patients with high risk prostate cancer (MRC PR08, ISRCTN78818544)



Results of the feasibility stage of STAMPEDE: a Multi-Arm, Multi-Stage phase II/III trial in patients with high risk prostate cancer (MRC PR08, ISRCTN78818544)








(PDF emailed within 1 workday: $29.90)

Accession: 021686617

Download citation: RISBibTeXText



Related references

Results of the feasibility stage of stampede: A multiarm, multi-stage phase II/III trial for patients with high risk prostate cancer (ISRCTN78818544). European Urology Supplements 7(3): 233, 2008

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 10(): 39-39, 2009

STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. Clinical Oncology ) 20(8): 577-581, 2008

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 2018

Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clinical Oncology 29(12): 778-786, 2017

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 13(): 168-168, 2013

Re: Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Journal of Urology 195(2): 350-350, 2016

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European Urology 67(6): 1028-1038, 2016

PD-154 An open-label, multi centre phase II, non-comparative trial of ZD1839 monotherapy in chemotherapy-naive patients with stage IV or stage III non-operable non-small cell lung cancer (NSCLC). Lung Cancer 49: S111-S112, 2005

An open-label, multi centre, phase II, non-comparative trial of ZD1839 monotherapy in chemotherapy-naive patients with stage IV or stage III non-operable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_suppl): 7098-7098, 2016

Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer 118(15): 3681-3690, 2012

The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial. European Urology Focus 3(1): 94-99, 2017

Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. International Journal of Radiation Oncology, Biology, Physics 86(3): 540-545, 2013

Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients. Tumori 103(3): 314-318, 2016

A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi-center phase II clinical trial, KLASS 03. Gastric Cancer, 2018